Cboe and Citadel File Lawsuit to Overturn CFTC Approval of Stock Perpetual Futures

What happened

Cboe Global Markets and Citadel Securities filed a lawsuit on November 4, 2026, challenging the CFTC's approval of stock perpetual futures for U.S. exchanges, just hours after the regulator greenlighted the contracts. The lawsuit places billions in potential trading volume in legal limbo and could slow the adoption of a product that Cboe views as a competitive threat to its existing derivatives franchise, particularly its index options complex. The legal action is consistent with Cboe's strategy of protecting its proprietary index and volatility products, which have driven recent revenue growth and account for the majority of derivatives revenue. However, the litigation introduces new regulatory and legal uncertainty for Cboe, as the outcome could affect the competitive landscape and may distract management from executing its strategic realignment and cost controls. While the master report already flagged litigation as a potential risk to the thesis, this proactive lawsuit by Cboe does not directly threaten its exclusive product rights but does add a layer of uncertainty to the investment case.

Implication

Over the next 6-12 months, the lawsuit could consume management attention and legal resources, and if Cboe is unsuccessful, stock perpetual futures could emerge as a new competitor for retail-oriented trading volume, potentially pressuring the growth of its index options business. Conversely, a successful legal challenge would reinforce Cboe's moat by delaying a new product that could fragment derivatives trading. However, the core drivers of Cboe's earnings—SPX and VIX options volumes, 0DTE adoption, and expense discipline—remain more important than this single legal skirmish. Investors should focus on Q3 2026 earnings for confirmation of volume trends and the Australia/Canada sale closing, while treating the lawsuit as a secondary risk that could affect sentiment if it drags on or yields an adverse ruling.

Thesis delta

The investment thesis remains WAIT, but the lawsuit introduces an incremental negative: it signals that management perceives perpetual futures as a genuine competitive threat, and the legal battle could distract from execution. Previously, the master report identified 'any disclosed regulatory or legal action that threatens exclusive index franchise rights' as a thesis breaker; however, this lawsuit is initiated by Cboe rather than against it, so it does not directly undermine the moat. Nevertheless, the increased legal and regulatory uncertainty slightly raises the risk profile and warrants monitoring, though it does not change the fundamental judgment of limited upside at the current price.